



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Rivastigmine 1A Pharma

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IAIN/0039	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	12/10/2022		Annex II and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



IA/0037/G	<p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p>	27/09/2022	n/a		
N/0036	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	07/09/2022		PL	
IA/0035/G	<p>This was an application for a group of variations.</p> <p>B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information</p> <p>B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength</p>	04/03/2022	n/a		

	<p>or pharmaceutical form</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p>				
IAIN/0034	A.1 - Administrative change - Change in the name and/or address of the MAH	26/01/2022		SmPC, Labelling and PL	
IAIN/0033	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	13/09/2021		Annex II and PL	
IAIN/0032/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)</p>	10/09/2021		Annex II and PL	
IA/0031/G	This was an application for a group of variations.	25/05/2021	n/a		

<p>B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p> <p>B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p> <p>B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p> <p>B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p> <p>B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p> <p>B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer</p> <p>B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates</p>				
--	--	--	--	--

	<p>exist per material)</p> <p>B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)</p> <p>B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)</p> <p>B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)</p> <p>B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)</p>				
IB/0030	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	21/09/2020	23/09/2021	SmPC, Annex II, Labelling and PL	
WS/1867/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>	03/09/2020	n/a		

	<p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS</p>				
PSUSA/2654/201901	Periodic Safety Update EU Single assessment - rivastigmine	05/09/2019	n/a		PRAC Recommendation - maintenance
IA/0028	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	08/08/2019	n/a		

WS/1493/G

This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.

26/04/2019

n/a

B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method

B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)

B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)

B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)

B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)

B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)

B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of

	<p>an obsolete parameter)</p> <p>B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation</p> <p>B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation</p> <p>B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation</p> <p>B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation</p>				
IA/0026/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size</p> <p>B.I.a.4.b - Change to in-process tests or limits</p>	29/03/2019	n/a		

	applied during the manufacture of the AS - Addition of a new in-process test and limits				
N/0024	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	18/10/2018	23/09/2021	Labelling	
WS/1139/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter</p> <p>B.II.d.1.d - Change in the specification parameters</p>	27/04/2017	n/a		

	<p>and/or limits of the finished product - Deletion of a non-significant specification parameter</p> <p>B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished product</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> <p>B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings</p>				
II/0022/G	This was an application for a group of variations.	09/02/2017	n/a		

A.7 - Administrative change - Deletion of manufacturing sites

B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions

B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place

B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place

B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation

B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS

B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS

B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS

B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS

<p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting</p>				
---	--	--	--	--

material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)

B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)

B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation

B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation

B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation

B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation

B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation

B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation

B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation

B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS

B.I.b.2.c - Change in test procedure for AS or

	starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS				
PSUSA/2654/201601	Periodic Safety Update EU Single assessment - rivastigmine	02/09/2016	n/a		PRAC Recommendation - maintenance
IB/0021/G	<p>This was an application for a group of variations.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference</p>	16/08/2016	25/07/2017	SmPC and PL	

	product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
PSUSA/2654/201501	Periodic Safety Update EU Single assessment - rivastigmine	24/09/2015	30/11/2015	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/2654/201501.
PSUSA/2654/201401	Periodic Safety Update EU Single assessment - rivastigmine	11/09/2014	n/a		PRAC Recommendation - maintenance
R/0016	Renewal of the marketing authorisation.	22/05/2014	19/08/2014	SmPC, Annex II, Labelling and PL	Based on the review of the cumulative efficacy and safety data available from clinical trials, post-marketing studies and spontaneous reports as well as the scientific literature, the CHMP concluded that there were no major changes to the known benefits and safety concerns associated with Rivastigmine Sandoz when used in the approved indication. The CHMP therefore concluded that the benefit/risk balance of Rivastigmine Sandoz remained favourable and recommended the renewal of the marketing authorisation with unlimited validity.
N/0017	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	01/04/2014	n/a		
IA/0015/G	This was an application for a group of variations.	28/08/2013	n/a		

	<p>B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer</p> <p>B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p>				
IAIN/0014/G	<p>This was an application for a group of variations.</p> <p>B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings</p> <p>B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings</p>	20/06/2013	n/a		
IAIN/0013	B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings	12/04/2013	06/05/2014	SmPC and PL	
II/0011	As a result of an open-label safety study in patients with Parkinson's disease dementia, new adverse reactions have been added in sections 4.8 of the SmPC with the frequency 'common': 'Decreased	18/10/2012	08/11/2012	SmPC and PL	Based on the result on a study conducted in patients with dementia due to Parkinson's disease requested by the CHMP, the MAH updated the product information for all formulation with new adverse reactions. Additionally, the

	<p>appetite', 'Hallucination, visual', 'depression', 'Hypokinesia', 'Cogwheel rigidity', 'Hypertension', Gait disturbance' and 'Parkinson gait'. 'Fall' has been included with a frequency of 'very common' and 'Hypotension' as 'uncommon' adverse reaction. Sections 4.3 and 4.4 were updated with information on skin application site reactions due to skin hypersensitivity, recommendations on formulation switching and treatment discontinuation. Update of the section 4.2 to include paediatric information to be in line with the originator. The Package Leaflet is updated accordingly. The requested variation proposed Update of Summary of Product Characteristics and Package Leaflet.</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p>				MAH updated the contraindications and warnings on skin reactions that may occur during the treatment with rivastigmine. The package leaflet has been amended to reflect those changes.
IB/0012/G	<p>This was an application for a group of variations.</p> <p>B.II.e.1.z - Change in immediate packaging of the finished product - Other variation</p> <p>B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation</p> <p>B.II.e.1.z - Change in immediate packaging of the finished product - Other variation</p>	01/08/2012	n/a		
II/0008/G	This was an application for a group of variations.	21/06/2012	21/06/2012		

	<p>To add an alternative manufacturing process for an intermediate.</p> <p>To add a specification to the active substance specifications.</p> <p>To delete an alternative method for testing.</p> <p>To delete a testing monograph for an intermediate.</p> <p>B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p>				
II/0006/G	This was an application for a group of variations.	19/01/2012	17/02/2012	SmPC and PL	Based on a review of the safety data for rivastigmine, new sides effects have been added in rivastigmine Summary of

	<p>The MAH propose to update section 4.8 of the SmPC to include new adverse reactions: dehydration, hepatitis, aggression, restlessness, sick sinus syndromes and anxiety. In addition, the whole section 4.8 has been revised according to the current MedDRA terminology.</p> <p>Furthermore, Section 4.4 of the SmPC has also been amended to include that gastrointestinal disorders may occur when in patients treated with rivastigmine and to include a warning for patients with low body weight.</p> <p>The Package Leaflet has been amended to reflect those changes.</p> <p>C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p>				<p>Product Characteristics (SmPC) with the frequency unknown: "dehydration", "hepatitis", "aggression", "restlessness", "sick sinus syndromes" and "anxiety".</p> <p>New warnings for patients with low body weight and patients who experience nausea, vomiting and diarrhoea have also been added in the SmPC.</p> <p>The Package Leaflet has been amended to reflect those changes.</p>
II/0005	<p>The MAH proposed to update sections 4.3 and 4.4 of SmPC to change the contraindication for patients with severe hepatic impairment into a warning. Section 4.4 of the SmPC was also revised to reflect that patients with clinically significant renal or hepatic impairment might experience more adverse reactions. Section 4.2 was amended accordingly. The</p>	19/01/2012	17/02/2012	SmPC and PL	<p>Based on a review of the safety data for rivastigmine, a warning has been added to the Product Information to reflect that patients with clinically significant renal or hepatic impairment might experience more adverse reactions.</p> <p>Patients with severe hepatic impairment have not been studied. However, rivastigmine may be used in this patient</p>

	<p>Package Leaflet has been amended to reflect those changes.</p> <p>In addition, minor linguistic amendments have been introduced in the SmPC, and the Package Leaflet of has been revised based on the results of a user testing.</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p>				population and close monitoring is necessary.
IAIN/0009	C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH	22/12/2011	n/a		
IA/0007/G	<p>This was an application for a group of variations.</p> <p>B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer</p> <p>B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p>	25/11/2011	n/a		
IA/0004/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including</p>	30/09/2011	n/a	Annex II and PL	

	<p>batch control/testing</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p>				
IB/0001	<p>Updated information on skin reactions has been included in section 4.8 of the SPC and the corresponding section 4 of the Package Leaflet. In addition, minor amendments have been made throughout the Annexes and the Product information has been brought in line with current QRD requirements.</p> <p>This followed a wider update to the Product information of Exelon (the reference medicinal product) which included updates of other formulations (i.e. patches) via procedure EMEA/H/C/000169/II/0055.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH</p>	25/08/2010	n/a	SmPC and PL	